Related Experiment Video
Updated: Apr 18, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Recent Advance in Drug Development of Squamous Cell Carcinoma
Abstract:
Squamous cell carcinoma (SCC) has a high worldwide incidence that is commonly seen as head and neck cancers, esophageal cancers, and non-small cell lung cancers. There is a poor prognosis for SCC due to potential recurrence and its metastatic tendency so the 5-year survival rate is very low. Target therapy is a novel and promising treatment strategy exhibiting great anti-tumor effects and survival benefits in SCC. This review summarizes current treatment strategies from clinical and experimental studies, including the agents targeting epidermal growth factor receptors, RNA polymerase, toll-like receptors, p38α MAPK, CXCR, and the related combination therapy regimens. However, there are still many challenges we have to face. It is a burning need to improve the development and availability of drug formulations.
Insights
Targeted therapy shows promise for treating squamous cell carcinoma (SCC), a common cancer with poor survival rates. Further development of drug formulations is crucial for improving treatment availability and patient outcomes.
Area of Science:
- Oncology
- Cancer Therapeutics
Background:
- Squamous cell carcinoma (SCC) presents a significant global health burden, frequently manifesting as head and neck, esophageal, and non-small cell lung cancers.
- Poor prognosis in SCC is attributed to high recurrence rates and metastatic potential, resulting in low 5-year survival.
- Targeted therapy offers a novel and promising treatment strategy with demonstrated anti-tumor effects and survival benefits in SCC.
Purpose of the Study:
- To review current clinical and experimental treatment strategies for squamous cell carcinoma.
- To highlight targeted agents and combination therapies for SCC management.
- To identify challenges and future directions in SCC drug development.
Main Methods:
- Comprehensive review of clinical and experimental studies on SCC treatment.
- Analysis of targeted agents including those against epidermal growth factor receptors, RNA polymerase, toll-like receptors, p38α MAPK, and CXCR.
- Evaluation of combination therapy regimens.
Main Results:
- Targeted therapies demonstrate significant anti-tumor activity and improve survival in SCC.
- Various molecular targets and combination strategies are under investigation.
- Challenges remain in optimizing drug formulation and availability.
Conclusions:
- Targeted therapy is a promising approach for improving SCC outcomes.
- Further research and development are needed to enhance drug formulations and accessibility.
- Addressing these challenges is critical for advancing SCC patient care.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...